Severity of Lesions Assessed by FFR in Coronary Disease: Is It Associated with Major Events?

severity of lesions ffrIn patients with coronary disease, the prognosis depends on the extent and reversibility of myocardial ischemia. Whether the outcome also depends on the severity of stenosis as determined by fractional flow reserve (FFR) has not been studied yet.

 

This study investigates the relationship between fractional flow reserve values and vessel-related events. Major adverse cardiovascular events (MACE) at 2 years were prospectively studied in 607 patients in whom all stenoses were assessed by FFR and who received medical therapy only.

 

Moreover, logistic regression models were used to calculate the decrease in the risk per 0.05 increase in FFR values.

 

Events were present for 272 (26.5%) of 1029 lesions. Lesions with stenosis diameter ≥70% were more often present in the group experiencing events (p <0.01).

 

The mean fractional flow reserve value was significantly lower in the group experiencing events than in the group with no events (0.68 vs. 0.80; p <0.01).

 

The cumulative incidence of MACE significantly increases with increasing FFR quartiles.

 

The average decrease in MACE per 0.05 increase in FFR was statistically significant, even after adjustment for all clinical and angiographic variables. The strongest increase in adverse events occurred for FFR values between 0.80 and 0.60. In a multivariate analysis, FFR was significantly associated with events at 2 years

 

Conclusion

In patients with stable coronary disease, functional severity of a lesion as assessed by fractional flow reserve is independently associated with major cardiovascular events.

 

Original title: A Prospective Natural History Study of Coronary Atherosclerosis Using Fractional Flow Reserve.

Reference: Emanuele Barbato et al. J Am Coll Cardiol. 2016;68(21):2247-2255.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....